Related Experiment Video
Updated: Feb 5, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer
Kelly E Henry1, Megan M Dacek2,3, Thomas R Dilling1
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Purpose:
Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly cancers, with a 5-year survival rate of less than 10%. Physicians often rely on biopsy or CT to guide treatment decisions, but these techniques fail to reliably measure the actions of therapeutic agents in PDAC. KRAS mutations are present in >90% of PDAC and are connected to many signaling pathways through its oncogenic cascade, including extracellular regulated kinase (ERK) and MYC. A key downstream event of MYC is transferrin receptor (TfR), which has been identified as a biomarker for cancer therapeutics and imaging.
Experimental Design:
In this study, we aimed to test whether zirconium-89 transferrin ([89Zr]Zr-Tf) could measure changes in MYC depending on KRAS status of PDAC, and assess target engagement of anti-MYC and anti-ERK-targeted therapies.
Results:
Mice bearing iKras*p53* tumors showed significantly higher (P < 0.05) uptake of [89Zr]Zr-Tf in mice withdrawn from inducible oncogenic KRAS. A therapy study with JQ1 showed a statistically significant decrease (P < 0.05) of [89Zr]Zr-Tf uptake in drug versus vehicle-treated mice bearing Capan-2 and Suit-2 xenografts. IHC analysis of resected PDAC tumors reflects the data observed via PET imaging and radiotracer biodistribution.
Conclusions:
Our study demonstrates that [89Zr]Zr-Tf is a valuable tool to noninvasively assess oncogene status and target engagement of small-molecule inhibitors downstream of oncogenic KRAS, allowing a quantitative assessment of drug delivery.
Insights
Zirconium-89 transferrin ([89Zr]Zr-Tf) PET imaging can noninvasively assess KRAS oncogene status and drug target engagement in pancreatic ductal adenocarcinoma (PDAC) models, aiding therapeutic assessment.
Area of Science:
- Oncology
- Molecular Imaging
- Cancer Therapeutics
Background:
- Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis with limited treatment monitoring tools.
- KRAS mutations drive PDAC, activating signaling pathways like ERK and MYC.
- Transferrin receptor (TfR) is a biomarker for cancer therapeutics and imaging, downstream of MYC.
Purpose of the Study:
- To evaluate [89Zr]Zr-Tf as a PET imaging agent to measure MYC changes related to KRAS status in PDAC.
- To assess target engagement of anti-MYC and anti-ERK therapies using [89Zr]Zr-Tf.
Main Methods:
- PET imaging with [89Zr]Zr-Tf in mouse models of PDAC with varying KRAS status.
- Therapy studies using JQ1 (an anti-MYC agent) in PDAC xenografts.
- Immunohistochemistry (IHC) analysis of resected tumors.
Main Results:
- [89Zr]Zr-Tf uptake was significantly higher in tumors with withdrawn oncogenic KRAS.
- JQ1 treatment led to a significant decrease in [89Zr]Zr-Tf uptake in xenografts.
- PET imaging data correlated with IHC findings.
Conclusions:
- [89Zr]Zr-Tf is a valuable tool for noninvasive assessment of oncogene status in PDAC.
- This radiotracer enables quantitative evaluation of drug delivery and target engagement for KRAS-pathway inhibitors.
Related Concept Videos
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Marcia's Theory of Identity Status
Persuasion Strategies
Coping Strategies: Problem Focused
For example, consider a student who struggles to understand their...
Pancreatic Juice and Secretion
When acidic chyme from the stomach enters the duodenum, it triggers the release of secretin, a hormone that prompts pancreatic juice secretion. After a fatty meal, cholecystokinin, another hormone, stimulates gallbladder contraction and enhances enzyme-rich...

